Our bodies continually produce cells to help us grow, replace dead cells, or heal damaged cells. Normally, cells grow and multiply in a sequence. However, damaged genes can develop abnormally. They can develop into masses called tumors. Tumors can be benign (non-cancerous) or malignant (cancerous). Benign tumors do not invade the body’s organs and surrounding tissues.
While the melanoma will develop, it may be confined to the original area. If these cells are left untreated or treated, they can invade beyond the original range and invade surrounding tissue, becoming invasive (metastatic) cancer.


A 2016 Cochrane Review meta-analysis of 257 studies and 5 RCT studies (human, randomized, double-blind, controlled trial) performed on 373 patient subjects. Results showed that patients using betaglucan, triterpen – Ganoderma are 1.27 times more likely to respond to chemotherapy or radiation (27%) compared to chemotherapy and radiation therapy alone.
This treatment response assessment was based on Who’s Response Criteria, which was used as the standard method for assessing tumor response to treatment. Evaluation depends on tumor size measurement, the change in tumor size after treatment is estimated from two-dimensional measurements. In addition, the analysis also used additional criteria for assessment of response in solid tumors (RECIST).


A very important difference between cancer cells and normal cells is that cancer cells are less differentiated. While normal cells grow, grow, mature, and differentiate into different types of cells that perform different functions, cancer cells are poor or do not differentiate. That is the reason why cancer cells can multiply and multiply – something normal cells don’t have. In addition, cancer cells are not affected by the body’s “signaling” to stop dividing, and they also exit a process known as “apoptosis” – the program of eliminating cells. unnecessary.
Based on these features, people have understood the mechanism of action on cancer cells of the active ingredient group betaglucan, triterpen from Linh Chi.

Cơ chế tác động lên tế bào ung thư của Betaglucan (Polysaccharides), Triterpenes

The five mechanisms of action on cancer cells of Triterpene – Linh Chi

Triterpenes – Ganoderma lucidum has been shown to induce cyclic arrest in phase G1 by downregulating Cyclin D1, and in phase G2 by blocking PKC activity. Triterpene also promotes apoptosis in cancer cell lines through a mitochondrial-dependent pathway followed by activation of caspase cascade. Triterpenes also suppressed tumor metastasis by modulating MMP and IL-8 and inhibiting inflammatory cytokine secretion in macrophage cells. Ultimately, triterpenes were found to act as an antioxidant by removing free radicals and enhancing innate antioxidant enzymes.

Three mechanisms of action on cancer cells of Betaglucan – Linh Chi

Betaglucan – Ganoderma lucidum has been shown to enhance immune response by stimulating the production of macrophages, NK cells and T lymphocytes. Like triterpenes, betaglucan can act as an antioxidant by reducing Oxidative damage caused by ROS and prevents DNA strand breakage. Betaglucan – Ganoderma lucidum also prevents tumor angiogenesis by reducing the proliferation of HUVEC and by inhibiting the secretion of vascular factors such as VEGF and TGF-β1.

Thus, Betaglucan Triterpen (Ganoderma lucidum) effectively supports chemotherapy cancer patients with the following benefits:

  • Increased response, decreased tumor size when used in combination with chemotherapy
  • Supports action on cancer cells with the following mechanisms:
    (1) Prevent the reproductive cycle, the cell division cycle of cancer cells
    (2) Prevent-reduce metastasis thanks to leukocytosis, support to destroy single cancer cells
    (3) Restriction of angiotensis progression – excessive vascular formation in cancer cells
    (4) Promote apotosis – programmed cell death cycle.

The most optimal benefit for cancer patients is Betaglucan Triterpene 1-2 days before chemotherapy.


(1) Jin, X., Beguerie, J. R., Sze, D. M. Y., & Chan, G. C. (2016). Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews, (6).

(2) Kao, C., Jesuthasan, A. C., Bishop, K. S., Glucina, M. P., & Ferguson, L. R. (2013). Anti-cancer activities of Ganoderma lucidum: active ingredients and pathways. Functional Foods in Health and Disease3(2), 48-65.

(3) Calviño, E., Pajuelo, L., de Eribe Casas, J. A. O., Manjón, J. L., Tejedor, M. C., Herráez, A., … & Diez, J. C. (2011). Cytotoxic action of Ganoderma lucidum on interleukin‐3 dependent lymphoma DA‐1 cells: involvement of apoptosis proteins. Phytotherapy Research25(1), 25-32.

Trả lời

Email của bạn sẽ không được hiển thị công khai. Các trường bắt buộc được đánh dấu *

Tư vấn kỹ - Phục hồi nhanh